Skip to content

JBIO JBIO Common Stock

Common Stock at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$9K0.0%
Vera Therapeutics logo
Vera TherapeuticsVERA
$72K+12.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$29K-3.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
200M0.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$6K0.0%
Vor Biopharma logo
Vor BiopharmaVOR
$19K+46.2%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's common stock?
JBIO (JBIO) reported common stock of $5K in Q1 2026.
How has JBIO's common stock changed year-over-year?
JBIO's common stock increased by 66.7% year-over-year, from $3K to $5K.
What is the long-term trend for JBIO's common stock?
Over 5 years (2020 to 2025), JBIO's common stock has grown at a -84.2% compound annual growth rate (CAGR), from $50M to $5K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).